Abstract: This disclosure describes a novel antibiotic designated Vermisporin produced in a microbiological fermentation using, for example, a new strain of Ophiobolus Vermisporus L-8. This novel antibiotic is an active antibacterial, especially anti-anaerobic bacterial agent.

Abstract: The antibiotic of the formula: ##STR1## wherein R is ##STR2## The antibiotic is useful for the treatment of swine dysentery and for promoting growth and/or increasing the efficiency of food utilization in poultry, swine and ruminants.

Abstract: Methods for using rapamycin in the treatment of certain cancers or tumors are disclosed.

Abstract: The invention concerns a method for suppressing bone marrow which comprises administering to a mammal at least one bone marrow suppressing complex of a radionuclide selected from the group consisting of Samarium-153, Gadolinium-159, and Holmium-166 and 1,4,7,10-tetraazacyclododecanetetramethylenephosphonic acid a physiologically acceptable salt thereof. Suitable compositions for use in this method are also provided.

Abstract: A K-252 compound represented by the formula: ##STR1## wherein R.sup.1 and R.sup.2 are independently H or OH; X represents COOH, COOR or CH.sub.2 OH; Y represents H, R or COR; and Z represents OH, OR or SR, wherein R represents lower alkyl has C-kinase inhibitory activity and is expected to be useful as an active ingredient of anti-tumor agents, etc.

Abstract: The present invention relates to methods and compositions for the control and prevention of helmintic, arthropod ectoparasitic and acaridal infections, in warm-blooded animals, such as meat-producing animals, and poultry, by administering to said animals a therapeutically or prophylactically-effective amount of new agents designated LL-F28249.alpha., .beta., .gamma., .delta., .epsilon., .zeta., .eta., .theta., .iota. and .omega., or mixtures thereof. The invention also relates to methods for the control of plant nematode infestations. These novel agents are produced via a controlled conditioned microbiological fermentation using Streptomyces sp. LL-F28249, having deposit accession number NRRL 15773.

Abstract: This invention relates to a compound, FR-900848, having antimicrobial activity against various microorganisms, to a process for the preparation of same and to a pharmaceutical composition comprising same.

Abstract: A novel complex designated herein as rigolettone complex is produced by fermentation of Streptomyces aburaviensis strain C-38,242 (ATCC 39290). The complex and its purified bioactive components, jildamycin and mantuamycin, exhibit antitumor activity in mouse tumor systems.

Abstract: Two strains of Streptomyces were identified as Streptomyces albovinaceous. Both isolates produced an antibiotic when grown in liquid culture medium containing homogenized oats. The antibiotic (Treponemycin) was isolated from the culture broth by solvent extraction and purified. The antibiotic showed inhibitory activity against several species of bacteria, especially Treponema hyodysenteriae, the causative agent of swine dysentery. In view of the oral 50% lethal dose of 400 mg/kg and its low MIC against four strains of T. hyodysenteriae, the antibiotic has value as a swine dysentery therapeutic. The antibiotic lends itself readily to production of a tetrahydro derivative, a primary amine, a dimethyl ester and a hydrochloride esters and salts of these compounds, and hydrates of these compounds and of the esters or salts can also be produced for pharmaceutical usages.

Abstract: This invention relates to methods and compositions for the control of protozoal infections in warm-blooded animals by administering to said animals a protozoacidally-effective amount of a new antibiotic designated LL-E19020.alpha., LL-E19020.beta. or a pharmaceutically and prophylactically acceptable salt thereof. The new antibiotics are produced by microbiological fermentation under controlled conditions using a new strain of Streptomyces lydicus subspecies tanzanius or mutants thereof.

Abstract: The present invention relates to methods for suppressing the nitrification of ammonium nitrogen in plant growth medium or soil and compositions which conserve soil nitrogen and supply soil nitrogen requirements necessary for plant nutrition.

Abstract: This invention relates to antibiotic LL-E19020.alpha. and LL-E19020.beta. derived from the microorganism Streptomyces lydicus subspecies tanzanius NRRL 18036, which are useful as an antibacterial agent.

Abstract: This invention provides methods for increasing the growth rate of meat producing animals, for improving the efficiency of feed utilization by said meat producing animals, and for increasing lactation in lactating ruminant animals. The invention also relates to novel animal feed compositions and parenteral compositions useful in obtaining the above-described desired results.

Abstract: A new substance K-259-2 having a molecular formula of C.sub.21 H.sub.18 O.sub.7, a molecular weight of 382 and an elemental analysis (%) of H: 4.50, C: 65.53 and N: 0. This substance is of interest in providing a new vasodilating agent in view of its ability to dilate the blood vessel, particularly the artery, of mammals. This substance may be obtained by fermentation of a microorganism Micromonospora sp. K-259 (FERM BP 569).

Abstract: New antibiotic substances arbitrarily designated M 9026 complex, antibiotic M 9026 factor 1, antibiotic M 9026 factor 2, and antibiotic M 9026 factor 3, produced by fermentation of a strain of the Micromonospora genus. The antibiotics of the invention are antimicrobial and antitumor agents.

Abstract: Orally administered compositions for altering lipid metabolism are described herein, these compositions containing an effective dose of cryptocidin. Also the method of altering lipid metabolism including reducing and controlling the blood cholesterol level, is described herein.

Abstract: The invention relates to a pharmaceutical composition for treating lymphocytic leukemia, melanoma or mammary carcinoma comprising an effective amount of FR-900216.

Abstract: A novel antibiotic for combating bacteria and promoting animal growth is obtained by cultivating Streptomyces strain BA 9.

Abstract: An antibiotic AM-5344-A.sub.2 substance, and a process for the preparation of the antibiotic AM-5344-A.sub.2 substance are described. The antibiotic AM-5344-A.sub.2 substance is prepared by cultivating an AM-5344-A.sub.2 substance-producing strain belonging to the genus Streptomyces, for example, Streptomyces sp. Am-5344 in a nutrient medium, and recovering the Am-5344-A.sub.2 substance from the culture.

Abstract: A novel antifungal antibiotic which has been designated EM5487 is prepared by cultivating Lysobacter gummosus A.T.C.C. No. 39472 under submerged aerobic conditions in an aqueous nutrient medium containing an assimilable carbohydrate and nitrogen source.

Abstract: A novel physiologically active substance K-252 having an antiallergic action is produced by culturing a microorganism of the genus Nocardiopsis.

Abstract: Antibiotic 81-484 of the following physico-chemical properties:(1) elementary analysis: C.sub.33 H.sub.48 O.sub.7 (high resolution mass spectrum);(2) molecular weight: 556 [Field desorption (FD) mass spectrum];(3) melting point: not clear (oily at 10.degree.-100.degree. C.);(4) specific rotation: [.alpha.].sub.D.sup.20 =-151.degree. (c=0.1, methanol);(5) ultraviolet absorption spectrum: shown in FIG. 1 (in methanol);(6) infrared absorption spectrum: shown in FIG. 2 (KBr tablet);(7) solubility: insoluble in hexane and water, soluble in diethyl ether, methanol, ethanol, dichloromethane, chloroform, ethyl acetate, butyl acetate, acetone and benzene;(8) nuclear magnetic resonance spectrum: shown in FIG. 3 (CDCl.sub.3, TMS);(9) nature: acidic substance;(10) color reaction:negative for ninhydrin, anthrone-H.sub.2 SO.sub.

Abstract: Novel antibiotics didemnins A, B and C (didemnins), and nordidemnins A, B and C (nordidemnins) which can be obtained from a marine organism. These antibiotics are active against a variety of DNA and RNA viruses; thus, they can be used in various environments to control or eradicate these viruses. Further, these antibiotics can be used to treat animals and humans hosting a neoplastic disease.

Abstract: This disclosure describes four new antibacterial agents designated LL-CO8078.alpha..sub.1, LL-CO8078.alpha..sub.2, LL-CO8078.alpha..sub.3 and LL-CO8078.beta. produced in a microbiological fermentation under controlled conditions using a new strain of a new species of the genus Streptomyces called Streptomyces majorciensis Labeda, sp. nov., and mutants thereof. These new antibacterial agents are active against a variety of microorganisms and thus are useful in inhibiting the growth of such bacteria wherever they may be found. In addition, these agents are active as growth promotants in warm-blooded animals.

Abstract: A novel antiviral antibiotic AM-2722 is described represented by the molecular formula C.sub.19 H.sub.26 NO.sub.3 Cl, and having the following physicochemical properties:(1) specific rotary power: [.alpha.].sub.D.sup.20 -0.5 (C-1, chloroform);(2) the UV spectrum shown in FIG. 1; and(3) the IR spectrum shown in FIG. 2.Also described is a process for producing the antiviral antibiotic AM-2722, wherein a microorganism of Streptomyces which has the ability to produce the antibiotic AM-2722 is cultured aerobically in a nutrient medium and the antibiotic AM-2722 accumulated in the medium and the microorganism cells is recovered.

Abstract: This invention relates to a novel antibiotic 76-11; process for the production thereof which comprises culturing an antibiotic 76-11 producing microorganism belonging to the genus Actinomadura to separate and collect the antibiotic; an anticoccidiosis agent comprising the antibiotic as an effective ingredient; and a growth accelerating and feed efficiency increasing agent for domestic animals and fowls comprising the antibiotic as an effective ingredient.

Abstract: This invention relates to the antibiotic stubomycin and process for producing same by culturing streptomyces sp KG - 2245 FERM-P No.

Abstract: Macbecin derivatives are produced by cultivating a microorganism of the genus Actinosynnema in a culture medium.The Macbecin derivatives are useful as antibacterial, antifungal or antiprotozoal agent.

Abstract: Orally administered compositions for altering lipid metabolism are described herein, these compositions containing an effective dose of endomycin. Also the method of altering lipid metabolism including reducing and controlling the blood cholesterol level, is described herein.

Abstract: Novel antibiotic U-64,815 producible in a fermentation under controlled conditions using a biologically pure culture of the microorganism Streptomyces microspinus, NRRL 12524. This antibiotic is active against various Gram-positive bacteria, for example, Staphylococcus aureus. It is also active against Haemophilus influenzae. Thus, antibiotic U-64,815 can be used in various environments to eradicate or control such bacteria.

Abstract: Macbecin derivatives are produced by cultivating a microorganism of the genus Actinosynnema in a culture medium.The Macbecin derivatives are useful as antibacterial, antifungal or antiprotozoal agent.

Abstract: Ravidomycin is produced by culturing Streptomyces ravidus NRRL 11,300 in an aqueous nutrient medium. Ravidomycin is useful as an antibacterial and antitumor agent. Methods for its preparation and use are disclosed.

Abstract: Antibiotic AY24,668 is producible by culturing Streptomyces hygroscopicus NRRL 5491 in an aqueous nutrient medium. AY24,668 has antifungal properties. Methods for its preparation and use are disclosed.

Abstract: Orally administered compositions for treating benign prostatic hypertrophy are described herein. These compositions contain an effective dose of N-acyl amphotericin B. Also, the method of treating benign prostatic hypertrophy with such compositions is described herein.

Abstract: Method and compositions for treatment of swine dysentery with antibiotic A-32887 (K-41). Antibiotic A-32887 is produced by submerged aerobic fermentation of Streptomyces albus NRRL 11109.

Abstract: Novel antibiotic U-62,162 producible in a fermentation under controlled conditions using a man-made biologically pure culture of the microorganism Streptomyces verdensis, Dietz and Li sp.n., NRRL 12256. This antibiotic is strongly active against various Gram-positive bacteria, for example, Staphylococcus aureus. Thus, antibiotic U-62,162 can be used in various environments to eradicate or control such bacteria.

Abstract: Disclosed are monoacyl and diacyl derivatives of rapamycin, processes for their preparation, methods of using the derivatives and pharmaceutical compositions of the derivatives. The derivatives are useful, inter alia, as antifungal antibiotics.

Abstract: The antibiotic MSD A63A, having antibacterial and growth-permittant activity, is produced by fermentation of Streptoverticillum hiroshimense MA4845 (ATCC 31586), in a suitable nutrient media.

Abstract: Methods and compositions for treatment of coccidiosis in poultry with antibiotic A-32887 (K-41). Antibiotic A-32887 is produced by submerged aerobic fermentation of Streptomyces albus NRRL 11109.

Abstract: Orally administered compositions for altering liquid metabolism are described herein, these compositions containing an effective dose of n-acyl amphotericin B. Also the method of altering lipid metabolism including reducing and controlling the blood cholesterol level, is described herein.

Abstract: A novel microorganism species belonging to the genus Micromonospora, i.e. Micromonospora sp. A 11725 is found to be capable of producing novel macrolide antibiotics A 11725 I, A 11725 II and A 11725 III. Novel antibiotics A 11725 Ia and A 11725 IIa are also found to be derived by chemical modification of the antibiotics A 11725 I and A 11725 II, respectively. All of these antibiotics or salts thereof exhibit excellent antibacterial and anti-mycoplasmal activities against various microorganisms such as Staphylococcus or Mycoplasma, and therefore useful for various purposes including medicaments.

Abstract: A method of treating inflammation comprising topical administration to mammals suffering from an inflammatory condition not associated with amicrobial component, employing selected antibiotics as the anti-inflammatory agent.

Abstract: Antibiotic A-39183 complex, comprising microbiologically active, related factors A, B, C, D, and E, is produced by submerged, aerobic fermentation of a new microorganism Streptomyces sp., NRRL 12049. The A-39183 antibiotics are closely related antibiotics. The individual A-39183 factors are separated by chromatography. The A-39183 factors are antibacterial agents which have activity against Staphylococcus and Streptococcus species that are penicillin resistant. The A-39183 factors are also active against both gram-positive and gram-negative anaerobic bacteria, and are ionophores.

Abstract: A new antibiotic named pamamycin is derived from S. alboniger. The antibiotic compound is neutral and terpene-like as derived from S. alboniger. The antibiotic is produced in conjunction with substances which either stimulate or inhibit the transition of substrate to aerial mycelia. Pamamycin may be separated by thin layer chromatography. The antibiotic displays particular R.sub.f values in thin layer chromatography as well as a particular antimicrobial spectrum for its use. The molecular formula is 621 and the elemental formula thereof is C.sub.36 H.sub.63 NO.sub.7 as determined by mass spectroscopy. The structure is believed to be a saturated alkane and terpene-like. In vivo tests with Staphylococcus aureus indicate that pamamycin is a potent inhibitor of both DNA and RNA synthesis and this antibiotic has present utility in a 1% solution to degerminate hospital walls.

Abstract: The invention relates to a novel metabolite, M.139603, of the empirical formula C.sub.35 H.sub.53 O.sub.8 Na, which is obtained from the aerobic fermentation of a novel Streptomyces species, NCIB 11426, and to the corresponding free acid form thereof, C.sub.35 H.sub.54 O.sub.8. M.139,603 reduces the proportion of methane produced by the "digestion" of food in the rumen of ruminant animals and increases the proportion of propionate to acetate in the rumen contents. The compound is therefore useful for increasing the growth rate of ruminant animals, and/or for increasing their efficiency of food conversion. The compound also possesses activity against Gram positive micro-organisms, and against coccidia, for example Eimeria tenella.

Abstract: Cephalosporins of the formula ##STR1## R represents hydrogen, sodium, potassium, or certain ester groups, R.sub.1 is in the .alpha.-configuration and is hydrogen or methoxy, X represents hydrogen ##STR2## R.sub.3 represents hydrogen or lower alkyl, R.sub.4 is hydrogen, lower alkyl, ##STR3## or --(CH.sub.2).sub.n --N--(lower alkyl).sub.2, R.sub.5 represents hydrogen, sodium or potassium, and n represents an integer from 1 to 4. These compounds are useful as antibacterial agents.

Abstract: Carriomycin and physiologically acceptable salts thereof are effective for the treatment and prophylaxis of swine dysentery.

Abstract: An antifibrotic substance P-1894B is produced by cultivating a microorganism belonging to the genus Streptomyces and being capable of producing P-1894B in a culture medium to have Antifibrotic substance P-1894B elaborated and accumulated in the cultured broth and recovering the substance.P-1894B is effective for the prophylaxis or treatment of the fibrosis due to excessive collagen accumulation in mammal.

Abstract: Novel antibiotic U-59,761 producible in a fermentation under controlled conditions using a biologically pure culture of the microorganism Saccharopolyspora hirsuta strain 367, NRRL 12045. This antibiotic is active against various microorganisms, for example, Staphylococcus aureus, Streptococcus pyogenes, Sarcina lutea, Klebsiella pneumoniae, Mycobacterium avium, and Bacteroides fragilis. Thus, antibiotic U-59,761 can be used in various environments to eradicate or control such bacteria.

Abstract: Antibiotic substances named saframycins A, B, C, D and E having antibacterial activity and activity against transplantable tumors. It is produced by cultivation of Streptomyces lavendulae strain No. 314.